Abstract
The discovery of the Philadelphia chromosome and its consistent involvement in chronic myeloid leukemia (CML) was the first time that a relationship between a cytogenetic abnormality and malignancy was demonstrated. This review will try to provide an insight into the molecular mechanisms underlying this disease and outline the therapeutical options for patients with CML.
MeSH terms
-
Bone Marrow Purging
-
Cell Transformation, Neoplastic / genetics
-
Cytogenetic Analysis
-
Fusion Proteins, bcr-abl / genetics
-
Fusion Proteins, bcr-abl / immunology
-
Genes, abl / genetics
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / genetics
-
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / immunology
-
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / pathology
-
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / therapy
-
Philadelphia Chromosome*
-
Signal Transduction / genetics